A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.



Status:Recruiting
Conditions:Dermatology
Therapuetic Areas:Dermatology / Plastic Surgery
Healthy:No
Age Range:12 - Any
Updated:2/2/2019
Start Date:October 20, 2018
End Date:April 30, 2021
Contact:Novartis Pharmaceuticals
Email:novartis.email@novartis.com
Phone:1-888-669-6682

Use our guide to learn which trials are right for you!

A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines

The purpose of this study is to establish efficacy and safety of ligelizumab in adolescent
and adult subjects with CSU who remain symptomatic despite standard of care treatment by
demonstrating better efficacy over omalizumab.

The study population will consist of approximately 1050 male and female subjects aged ≥ 12
years who have been diagnosed with CSU and who remain symptomatic despite the use of
H1-antihistamines. Of these, approximately 1000 adults and 50 adolescents are planned for
inclusion in the study.

This is a multi-center, randomized, double-blind, active- and placebo-controlled,
parallel-group study. There is a screening period of up to 28 days, a 52 week double-blind
treatment period, and a 12 week post-treatment follow-up period.


Key Inclusion Criteria:

- Signed informed consent must be obtained prior to participation in the study. The
subject's', parent'ssubject's, parent's or legal guardian's signed written informed
consent and child's assent, if appropriate, must be obtained before any assessment is
performed. Of note, if the subject reaches age of consent (age as per local law)
during the study, they will also need to sign the corresponding study Informed Consent
Form (ICF) at the next study visit.

- Male and female subjects ≥ 12 years of age at the time of screening.

- CSU diagnosis for ≥ 6 months.

- Diagnosis of CSU refractory to H1-AH at approved doses at the time of randomization,
as defined by all of the following:

- The presence of itch and hives for ≥ 6 consecutive weeks at any time prior to Visit 1
(Day - 28 to Day -14) despite current use of non-sedating H1-AH

- UAS7 score (range 0-42) ≥ 16 and HSS7 (range 0-21) ≥ 8 during the 7 days prior to
randomization (Visit 110, Day 1)

- Subjects must be on H1-AH at only approved doses for treatment of CSU starting at
Visit 1 (Day -28 to Day -14)

- Willing and able to complete a daily symptom eDiary for the duration of the study and
adhere to the study visit schedules.

Key Exclusion Criteria:

- History of hypersensitivity to any of the study drugs or their excipients or to drugs
of similar chemical classes (i.e. to murine, chimeric or human antibodies).

- Subjects having a clearly defined cause of their chronic urticaria, other than CSU.
This includes, but is not limited to, the following: symptomatic dermographism
(urticaria factitia), cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic-,
cholinergic- or contact-urticaria.

- Diseases, other than chronic urticaria, with urticarial or angioedema symptoms such as
urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria
pigmentosa) and hereditary or acquired angioedema (eg, due to C1 inhibitor
deficiency).

- Subjects with evidence of helminthic parasitic infection as evidenced by stools being
positive for a pathogenic organism according to local guidelines. All subjects will be
screened at Visit 1. If stool testing is positive for pathogenic organism, the subject
will not be randomized and will not be allowed to rescreen.

- Any other skin disease associated with chronic itching that might influence in the
investigators opinion the study evaluations and results (e.g. atopic dermatitis,
bullous pemphigoid, dermatitis herpetiformis, senile pruritus, etc.).

- Prior exposure to ligelizumab or omalizumab.

- Any H2 antihistamine, LTRA (montelukast or zafirlukast) or H1 antihistamines use at
greater than approved doses after Visit 1.
We found this trial at
16
sites
Birmingham, Alabama 35209
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Baltimore, Maryland 21287
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Bellingham, Washington 98225
?
mi
from
Bellingham, WA
Click here to add this to my saved trials
Blue Bell, Pennsylvania 19422
?
mi
from
Blue Bell, PA
Click here to add this to my saved trials
Brighton, Massachusetts 02135
?
mi
from
Brighton, MA
Click here to add this to my saved trials
Darlinghurst, New South Wales 2010
?
mi
from
Darlinghurst,
Click here to add this to my saved trials
El Paso, Texas 79902
?
mi
from
El Paso, TX
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Los Angeles, California 90095
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Murray, Utah 84107
?
mi
from
Murray, UT
Click here to add this to my saved trials
Normal, Illinois 61761
?
mi
from
Normal, IL
Click here to add this to my saved trials
North Charleston, South Carolina 29420
?
mi
from
North Charleston, SC
Click here to add this to my saved trials
Papillion, Nebraska 68046
?
mi
from
Papillion, NE
Click here to add this to my saved trials
Sarasota, Florida 34239
?
mi
from
Sarasota, FL
Click here to add this to my saved trials
Tampa, Florida 33613
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Toledo, Ohio 43606
?
mi
from
Toledo, OH
Click here to add this to my saved trials